SELLAS Life Sciences Group, Inc. — Director's Dealing 2012

Apr 17, 2012

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Galena Biopharma, Inc. (GALE)
CIK: 0001390478
Period of Report: 2012-02-01

Reporting Person: MAZANET ROSEMARY (Chief Medical Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$0.72	2022-01-12	Common Stock (200000)		Direct

Footnotes

F1: Option vests in 16 equal quarterly installments beginning three months from January 12, 2012.

F2: Represents the closing price of the Company's stock on January 12, 2012.